Monte Rosa Therapeutics is a biopharmaceutical firm with an advanced focus on discovering new small molecule precision drugs that selectively degrade relevant proteins for therapeutic purposes. They are developing numerous treatments for several diseases like cancers, diabetes, neurodegenerative diseases, Crohn's disease, liver disease, and autoimmune diseases. Their molecular glue degrader for GSPT1 is targeted at treating Myc-driven cancers and is taken orally.